Corton Capital’s Dianthus Therapeutics DNTH Stock Holding History

Corton Capital’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-759	Closed	-$35K	–	378
2022 Q1	$35K	Buy	+759	New	+$41.5K	0.02%	422

Other funds holding DNTH

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Corton Capital's DNTH Position: Q2 2022 in Review

Corton Capital sold out of Dianthus Therapeutics (DNTH) in Q2 2022, closing a stake of 759 shares — an estimated $35K sold.

Corton Capital first reported a position in DNTH in Q1 2022 and held it in 1 quarter. The position peaked at $35K in Q1 2022. 75 funds tracked by Wall St. Rank hold DNTH as of Q2 2022.

Corton Capital reported no remaining Dianthus Therapeutics position as of Q2 2022 after selling out during the quarter.
Corton Capital sold 759 Dianthus Therapeutics shares in Q2 2022, an estimated $35K.
Corton Capital first reported a position in Dianthus Therapeutics in Q1 2022 and held it in 1 quarter.
Corton Capital's Dianthus Therapeutics position peaked at $35K in Q1 2022.
75 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2022.

Based on Corton Capital's 13F filing for Q2 2022, filed 15 Aug 2022.